These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 26386078)

  • 1. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
    Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
    Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
    Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
    PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
    Seol H; Lee HJ; Choi Y; Lee HE; Kim YJ; Kim JH; Kang E; Kim SW; Park SY
    Mod Pathol; 2012 Jul; 25(7):938-48. PubMed ID: 22388760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
    Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
    PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
    Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
    J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?
    Tognela A; Beith J; Kiely B; Bastick P; Lynch J; Descallar J; Mok K
    Clin Breast Cancer; 2015 Aug; 15(4):277-84. PubMed ID: 25676930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.